197,500 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by Cutter Capital Management LP

Cutter Capital Management LP acquired a new position in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 197,500 shares of the company’s stock, valued at approximately $8,212,000. Moderna makes up approximately 3.4% of Cutter Capital Management LP’s portfolio, making the stock its 15th largest position. Cutter Capital Management LP owned approximately 0.05% of Moderna as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MRNA. Cetera Investment Advisers boosted its position in shares of Moderna by 8.3% during the 4th quarter. Cetera Investment Advisers now owns 40,783 shares of the company’s stock worth $1,696,000 after purchasing an additional 3,121 shares in the last quarter. Cantor Fitzgerald L. P. bought a new stake in shares of Moderna during the fourth quarter valued at approximately $705,000. Banque Transatlantique SA acquired a new position in shares of Moderna during the fourth quarter worth approximately $2,858,000. BLI Banque de Luxembourg Investments bought a new stake in Moderna during the 4th quarter valued at $591,000. Finally, Ameriprise Financial Inc. lifted its stake in shares of Moderna by 10.8% in the fourth quarter. Ameriprise Financial Inc. now owns 235,280 shares of the company’s stock valued at $9,784,000 after buying an additional 23,007 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Up 0.8 %

NASDAQ:MRNA opened at $27.84 on Tuesday. The stock has a market cap of $10.76 billion, a P/E ratio of -3.00 and a beta of 1.99. The business’s 50-day moving average price is $29.40 and its two-hundred day moving average price is $37.16. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping analysts’ consensus estimates of ($2.92) by $0.40. The business had revenue of $108.00 million during the quarter, compared to analysts’ expectations of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business’s quarterly revenue was down 35.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($3.07) EPS. On average, equities research analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MRNA. Berenberg Bank increased their price objective on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday, January 16th. JPMorgan Chase & Co. lowered their target price on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a report on Friday, March 21st. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Bank of America decreased their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada dropped their target price on shares of Moderna from $32.00 to $28.00 and set a “sector perform” rating on the stock in a research note on Friday. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $53.95.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.